OMA 2023 Spring Summit: Antiobesity Pharmacotherapy: A Series of Real Patient Cases (On Demand) PB24
This session will examine the use of on-label anti-obesity pharmacotherapy to treat obesity. Through real patient cases seen at our center, we will explore complex patient scenarios and discuss combining advanced therapies. We will also explore advanced scenarios such as how to approach medication-induced weight gain, or weight regain after bariatric surgery.
CME/CE Expiration Date: 4/23/26
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
(Ref #123)
Mohini Aras, MD and Sarah Barenbaum, MD
The Obesity Medicine Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.